| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 63629-6709-02 | 63629-6709 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug 28, 2015 | In Use | |
| 55154-0217-06 | 55154-0217 | conjugated estrogens | Premarin | 0.3 mg/1 | Hormonal Therapy | Estrogen | Oral | Jan 1, 2006 | Feb 28, 2014 | No Longer Used | |
| 72789-0393-05 | 72789-0393 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jun 24, 2024 | In Use | |
| 68071-1968-03 | 68071-1968 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb 23, 2017 | Dec 31, 2019 | No Longer Used |
| 46708-0618-31 | 46708-0618 | Cyclophosphamide | Cyclophosphamide | 25.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Oral | Nov 23, 2022 | In Use | |
| 00904-7444-61 | 00904-7444 | Dexamethasone | Dexamethasone | 2.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug 26, 2024 | In Use | |
| 70771-1521-03 | 70771-1521 | Erlotinib | Erlotinib | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Apr 30, 2020 | In Use | |
| 71205-0908-11 | 71205-0908 | LEUCOVORIN CALCIUM | LEUCOVORIN CALCIUM | 5.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | Jul 16, 2021 | In Use | |
| 61919-0218-10 | 61919-0218 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan 1, 2014 | In Use | |
| 63187-0037-05 | 63187-0037 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug 1, 2014 | In Use | |
| 31722-0264-30 | 31722-0264 | ERLOTINIB | ERLOTINIB | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | May 24, 2024 | In Use | |
| 00378-5260-98 | 00378-5260 | Temozolomide | Temozolomide | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jun 29, 2016 | Mar 31, 2018 | No Longer Used |
| 55289-0761-30 | 55289-0761 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Dec 21, 2009 | Nov 23, 2021 | No Longer Used | |
| 42388-0023-36 | 42388-0023 | Cabozantinib | CABOMETYX | 60.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Nov 16, 2017 | In Use | |
| 68071-1904-03 | 68071-1904 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb 22, 2017 | In Use | |
| 68071-3202-09 | 68071-3202 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | May 11, 2017 | Dec 31, 2019 | No Longer Used | |
| 76189-0534-90 | 76189-0534 | Ponatinib Hydrochloride | Iclusig | 45.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Dec 14, 2012 | Jul 26, 2020 | No Longer Used |
| 62332-0730-31 | 62332-0730 | METHOTREXATE | METHOTREXATE | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Jun 4, 2024 | In Use | |
| 68788-8663-05 | 68788-8663 | PREDNISONE | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 13, 2024 | In Use | |
| 68788-9901-09 | 68788-9901 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Feb 13, 2012 | Sep 9, 2019 | No Longer Used | |
| 69452-0350-01 | 69452-0350 | Granisetron Hydrochloride | Granisetron Hydrochloride | 1.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb 28, 2022 | In Use | |
| 65862-0390-19 | 65862-0390 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Apr 12, 2010 | In Use | |
| 68788-9179-08 | 68788-9179 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jul 21, 2011 | Feb 22, 2019 | No Longer Used |
| 00002-5340-60 | 00002-5340 | Selpercatinib | RETEVMO | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, RET | Oral | Apr 10, 2024 | In Use | |
| 00093-0220-01 | 00093-0220 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Jul 6, 2009 | Oct 31, 2019 | No Longer Used |
Found 12393 results — Export these results
Home